Effects of Meglumine adenosine cyclophosphate combined with Metoprolol in treatment of patients with ventricular arrhythmia
Objective:To investigate effects of Meglumine adenosine cyclophosphate combined with Metoprolol in treatment of patients with ventricular arrhythmia.Methods:A prospective study was conducted on 80 patients with ventricular arrhythmia admitted to the hospital from May 2021 to January 2023.According to the random number table method,they were divided into control group and study group,40 cases in each group.The control group was treated with Metoprolol tartrate sustained-release tablets,while the study group was treated with Meglumine adenosine cyclophosphate for injection on the basis of that of the control group.The clinical efficacy,the cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)]levels,the myocardial injury markers[cardiac troponin I(cTnI),creatine kinase isoenzyme(CK-MB),brain natriuretic peptide(BNP)]levels,the heart rate variability indexes[standard deviation of NN intervals(SDNN),standard deviation of the average NN intervals(SDANN),root mean square successive differences between successive R-R interval(RMSSD)]levels,the vascular endothelial function indexes[endothelin-1(ET-1),homocysteine(Hcy)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 90.00%(36/40),which was higher than 72.50%(29/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the LVEF,SDNN,SDANN and RMSSD values of the study group were higher than those of the control group,the LVESD and LVEDD values were lower than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of serum ET-1,Hcy,cTnI,CK-MB and BNP in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the study group was 10.00%(4/40),which was lower than 32.50%(13/40)in the control group,and the difference was statistically significant(P<0.05).Conclusions:Meglumine adenosine cyclophosphate combined with Metoprolol in the treatment of the patients with ventricular arrhythmia can improve cardiac function and the heart rate variability,inhibit the ventricular remodeling,promote the recovery of heart rhythm,reduce the vascular endothelial function and the myocardial tissue damage,and reduce the incidence of adverse reactions.Moreover,it is superior to single Metoprolol treatment.
万方数据
维普
